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Should We Still Subcategorize Helicobacter pylori- 
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ㅋ
Functional dyspepsia is a group of disorders featuring symptoms believed to be derived from the stomach and duodenum 
such as upper abdominal discomfort, pain, postprandial fullness and early satiety. A key diagnostic requisite is the absence of 
organic, metabolic, or systemic disorders to explain “dyspeptic symptoms.” Therefore, when peptic ulcer diseases (including 
scars), erosive esophagitis and upper gastrointestinal malignancies are found at endoscopic examinations, the diagnosis of 
functional dyspepsia is excluded. One notable exception, however, is Helicobacter pylori infection. According to the Rome III 
definition, H. pylori infection is included in functional dyspepsia. This is an obvious deviation from the diagnostic principle of 
functional dyspepsia, since H. pylori infection is a definite cause of mucosal inflammation, which affects a number of im-
portant gastric physiologies such as acid secretion, gastric endocrine function and motility. The chronic persistent nature of in-
fection also results in more dramatic mucosal changes such as atrophy or intestinal metaplasia, the presence of which in the 
esophagus (Barrett’s esophagus) precludes the diagnosis of functional dyspepsia. Since careful endoscopic examination can di-
agnose reliably H. pylori infection not only in Japan but also in Western contries, it is now feasible and more logical to ex-
clude patients with chronic gastritis caused by H. pylori infection as having dyspeptic symptoms. It is time to establish the 
Asian consensus to declare that H. pylori infection should be separated from functional dyspepsia.
(J Neurogastroenterol Motil 2011;17:366-371)
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Introduction
Definition of functional dyspepsia (FD) has been revised in 
the past to better delineate the disorder, and most recently, inter-
nationally accepted definition is the so-called Rome III criteria 
proposed by the Rome III committees.
1 In the documents, it was 
stated that “functional dyspepsia is defined as the presence of one 
or more dyspepsia symptoms that are considered to originate 
from the gastroduodenal region, in the absence of any organic, 
systemic or metabolic disease that is likely to explain the symp-
toms.”
1 They also propose 2 subgroups according to the symp-
toms: postprandial distress syndrome which includes bothersome 
postprandial fullness and/or early satiation as the main symptoms 
and epigastric pain syndrome that includes pain or burning lo-
calized to the epigastrium as the major symptom. However, 
heartburn, which had been included as a symptom of dyspepsia in 
the past, was excluded from symptom constellation of dyspepsia, H. pylori Infection and Functional Dyspepsia
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Table 1. Exclusion Criteria Reported in Trials Examining the 










McColl K et al
5 XX OO
Blum AL et al
6 XX △
a N/D
Talley NJ et al
9 XX △
a X
Talley NJ et al
10 XX △
a X
Miwa H et al
11 XX X N / D
Froehlich F et al
12 XX XX
Koskenpato J et al
13 XX XX
Hsu PI et al
14 XX XX
Bruley des Varannes S et al
15 XXN / D N / D
Malfertheiner P et al
16 XX XX
Koeltz HR et al
17 XX △
b N/D
Gisbert JP et al
18 XXN / D N / D
O, included; X, excluded (including history and/or scar); △
a, excluded if there
are more than 5 erosions; △
b, excluded if there are more than 10 erosions; N/D, 
not described.
Gastrointestinal malignancies were excluded in all the trials.
Table 2. Exclusion Criteria Reported in Trials Examining the 










Talley NJ et al
19 XX△
a N/D
Farup PG et al
20 XX△
a N/D
Blum AL et al
21 XX△
b N/D
Bolling-Sternevald E et al
22 XX△
a N/D
Wong WM et al
23 XX X X
Peura DA et al
24 XX△
a X
Veldhuyzen van X X N/D N/D
  Zanten S et al
25
O, included; X, excluded (including history and/or scar); △
a, excluded if there
are more than 5 erosions; △
b, excluded if there are more than 10 erosions; N/D, 
not described.
Gastrointestinal malignancies were excluded in all the trials.
although it may coexist with dyspeptic symptoms.
Current Rome III Definition for Functional 
Dyspepsia Is Not Satisfactory in Many 
Clinical Situations
How can you ascertain the absence of organic, systemic or 
metabolic diseases? They recommend the first diagnostic ap-
proach to exclude structural causes of dyspepsia presumed to be 
originating in the gastroduodenal region with upper gastro-
intestinal endoscopy. By endoscopic examination, erosive reflux 
esophagitis, upper gastrointestinal malignancies and peptic ulcer 
diseases (including scars) can be identified and hence excluded 
with no need to consider whether the symptoms are truly caused 
by these organic diseases or not. Indeed, if you find peptic ulcer 
or early gastric cancer at the examination, how can you be certain 
that long-standing dyspeptic symptoms are actually caused by the 
organic diseases? There are a number of reports that almost half 
of the peptic ulcers were asymptomatic and the majority of early 
gastric cancers was asymptomatic.
2,3 Nevertheless current criteria 
for excluding the diagnosis of FD do not require the proof that 
identified organic diseases are the actual cause of dyspeptic symp-
toms. For example, if a patient continues to complain of dyspeptic 
symptoms after complete healing of peptic ulcer diseases either by 
stopping non-steroidal anti-inflammatory drugs (NSAIDs) or by 
eradicating Helicobacter pylori, should they be excluded as having 
functional dyspepsia? This issue has not been addressed by the 
Rome III definition.
On the other hand, higher rates of occurrence of peptic ulcer 
diseases (PUD) in H. pylori-positive patients diagnosed with 
“non-ulcer dyspepsia” or FD have been reported.
4-7 Once they 
develop PUD, then would their diagnosis be changed from FD 
to PUD? If those H. pylori-positive patients with dyspepsia turn 
out to be categorized as having PUD, the published meta-analy-
sis
8 reporting the effects of eradication therapy would require 
re-evaluation by excluding those who developed PUD.
There also are grey-zones of defining organic diseases. For 
example, if you find a patient with erosive gastritis, will you defer 
the diagnosis of functional dyspepsia? According to review of the 
inclusion and exclusion criteria in the past clinical trials, there are 
notable inconsistencies on the inclusion of gastric erosions. When 
clinical trials of non-ulcer dyspepsia/functional dyspepsia to study 
the effect of eradication therapy that were selected for meta-analy-
sis
8 were compared, there was notable inconsistencies in the ex-
clusion criteria (Table 1).
9-18 Similarly, the exclusion criteria 
adopted in clinical trials for studying the effect of proton pump 
inhibitors are not uniform for gastric erosions (Table 2).
19-25 In 
some trials, the number of erosions (such as over 5 erosions) was 
an exclusion criterion, but not others. In most of them, however, 
duodenal erosion was an exclusion criterion. To further compli-
cate the matter, the distinction between erosion and ulcer is often 
arbitrarily defined in clinical trials examining the effects of an-
ti-ulcer regimens for NSAIDs prevention; some use mucosal de-
fect over 3 mm while others use 5 mm.
26 Thus it might be possi-
ble that the “erosions” in these trails were defined as ulcer if mu-Kentaro Sugano
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Figure 1. Endoscopic features of nod-
ular gastritis. Note diffuse whitish elevat-
ions on the distal gastric mucosa (A, 
white light), which can be further en-
hanced by flexible spectral imaging color 
enhancement mode of observation (B).
cosal defects were more than 3 mm. A recent meta-analysis,
27 
however, did not include gastroduodenal erosions as clinically 
significant findings without any legitimate explanation, although 
erosive esophagitis was considered as a significant finding.
Gastric or duodenal erosions have structural changes easily 
identifiable by routine endoscopic examinations. As shown in the 
previous clinical trials, there were a number of inconsistencies for 
dealing with these conditions (Tables 1 and 2). From my point of 
view, it seems logical to exclude these obvious mucosal changes 
from functional diseases, although there is no conclusion how to 
handle these conditions based on solid evidence.
Helicobacter pylori Infection Is 
an Organic Disease
In the current Rome III definition, H. pylori infection is not 
an exclusion criterion of functional dyspepsia. This is an obvious 
deviation from the definition, because H. pylori infection causes 
definite microscopic and/or macroscopic changes in the gastric 
mucosa with its consequence on alterations in gastric physio-
logies. H. pylori strains predominant in the North Eastern Asia 
are more virulent than other parts of the world and together with 
life-style factors, frequently cause severe phenotypes such as atro-
phy, intestinal metaplasia leading to gastric cancer,
28,29 These 
mucosal changes are obvious even with conventional endoscopic 
examinations. A unique type of gastritis due to H. pylori infection, 
so-called nodular gastritis (Fig. 1), is also easily detected by rou-
tine endoscopic examinations, and can be confirmed by dye-spray 
method.
30,31 Importantly, patients with this particular form of 
gastritis have a high percentage of dyspeptic symptoms, which re-
solve with eradication therapy accompanied with disappearance 
of goose-flesh appearance.
30,31 Another example is the enlarged 
fold gastritis with hypochlorhydria, although no specific symp-
tom of this condition have been described.
32 Functional as well as 
histological changes were reported to be restored by eradication 
therapy, indicating H. pylori infection is the cause of structural as 
well as functional changes seen in enlarged fold gastritis. More 
conspicuous macroscopic changes such as atrophy and intestinal 
metaplasia are frequently observed in Japan where more virulent 
strains are predominant.
28,29 Indeed in a report from Japan, a 
number of other mucosal disorders was identified by routine ex-
aminations for dyspeptic patients.
33 Thus, H. pylori infection 
causes definite structural changes, fulfilling the definition for or-
ganic disease in many patients in Japan. It may be argued, how-
ever, that in the majority of H. pylori infection in the West, the 
subtlety of mucosal changes may evade reliable diagnosis and 
hence preclude exclusion by routine endoscopic examination. 
However, it has been reported not only in Japan but also in 
Europe that with the use of high-resolution endoscopy coupled 
with magnification can identify infection status of H. pylori with 
high accuracy.
34,35 Therefore, if trained adequately, it is now fea-
sible to predict the presence of H. pylori infection by identifying 
the regular arrangement of collecting venules (so-called “RAC” 
pattern) during routine endoscopic examinations. Even when the 
gastric mucosa is judged “normal” with routine endoscopic ex-
aminations by inexperienced hands, the diagnosis of H. pylori in-
fection can still be established with other modalities such as urea 
breath test or serology.
Irrespective of the macroscopic appearance, inflammatory 
cell infiltrates with elevated levels of inflammatory cytokines are 
demonstrated by histology and cytokine assays. How can we call 
such an inflammatory mucosa with obvious microscopic and/or 
macroscopic (endoscopic) changes as non-organic disorders?
H. pylori infection also causes profound alteration in gastric 
physiology. Acid secretion during H. pylori infection depends 
upon the spread of atrophy and the local inflammatory states, 
which may be determined by complex host-bacterial interactions 
and environmental factors.
36 In a subset of H. pylori-infected pa-H. pylori Infection and Functional Dyspepsia
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Figure 2. Concept of coexistence of functional disorder with organic 
diseases. Dyspepstic subjects caused by specific organic causes are 
shown as graded dark area in the bar representing the population. 
Patients with severe symptoms are depicted darker in the right side of the
bars. Unexplained persistent dyspeptic symptoms may be unraveled 
only after removal of the causative diseases or drugs. In peptic ulcer 
diseases (A), for example, a proportion of patients with dyspeptic 
symptoms may represnt the majority. In contrast, the proportion of 
symptomatic patients may be smaller in non-steroidal anti-inflammatory
drug users (B) and in subjects with chronic gastritis (C). After curing 
the diseases or stopping the drugs responsible for the symptoms, some 
subjects may still continue to be symptomatic (indicated as a light grey 
part of the bars on the right side panels). This group of subjects may be
considered as having functional dyspepsia. In this concept, organic 
diseases and functional diseases are not mutually exclusive and may 
coexist. PUD, peptic ulcer Diseases; NSAID, non-steroidal anti- 
inflammatory drug; HP, Helicobacter pylori.
tients with antral predominant gastritis without corpus atrophy, 
acid secretion might be higher than normal and can be a cause of 
dyspeptic symptoms.
37,38 As demonstrated by a small but sig-
nificant effect of proton pump inhibitors,
39,40 alterations in acid 
secretion can be a cause of symptoms in a subset of patients with 
H. pylori infection. Conversely, when atrophy extends into the 
corpus mucosa, diminished acid secretion has been shown to pro-
tect reflux diseases and hence may suppress a component of re-
flux-like symptoms of dyspepsia.
41
Moreover, H. pylori infection affects an important gastric en-
docrine function, such as ghrelin dynamics.
42 Since ghrelin is im-
portant in the regulation of food intake as well as gastrointestinal 
motility, the alteration of ghrelin status in the stomach might be 
contributive to dyspeptic symptoms. Indeed, alteration of ghrelin 
levels in functional dyspepsia has been reported, though the path-
ophysiological significance remains to be elucidated.
43 Both acid 
secretion and ghrelin status can be reversed to some extent by 
eradication therapy,
44-46 and restoration of these physiological 
changes may explain the beneficial effect of eradication therapy 
on dyspeptic symptoms in H. pylori infection.
Gastric motility may be linked to H. pylori infection in a sub-
set of patients as demonstrated in human studies,
47,48 although no 
correlation between gastric emptying to eradication therapy was 
reported by others.
49 Further investigations into detailed mecha-
nisms to explore the changes in various regulatory factors such as 
ghrelin and/or inflammatory cytokines linking to observed im-
provement should be required.
Proposal for Conceptual Consistency
H. pylori is a pathogen invoking chronic inflammation in the 
gastric mucosa associated with multiple alterations in gastric 
functions. Careful endoscopic examinations enable to identify 
mucosal changes caused by H. pylori infection. Therefore it will 
fit in a definite organic disease and should not be labeled as a 
functional disease. However, we might still see some patients 
having been cured of “organic diseases” remain dyspeptic. How 
can we reconcile such conflicting conditions? One idea is to speci-
fy the component of symptoms caused by organic diseases which 
should be resolved by a specific treatment. For example, if pa-
tients with dyspepsia who were recently prescribed NSAIDs were 
found to have PUD, they will be excluded from the diagnosis of 
functional dyspepsia. If patient who is negative for H. pylori in-
fection has dyspeptic symptoms before taking NSAIDs and were 
negative for H. pylori infection and continues to complain similar 
symptoms after cessation of NSAIDs and cure of the ulcer, could 
you still regard the symptoms are due to PUD and preclude the 
diagnosis of FD? In such cases, residual or persistent symptoms 
of the patients might be better explained by accepting that they 
had overlapping functional dyspepsia. Similarly, patients with H. 
pylori infection should have specific symptoms ascribed to the in-
fection, a typical example of which is nodular gastritis as de-
scribed previously. Thus, effects of eradication may depend on 
the ratio of H. pylori infection contributing the symptoms of pa-
tients (Fig. 2). In this context, it might be plausible that erad-
ication therapy showed greater symptomatic benefits in Asian tri-
als
50 where more virulent strains causing severe mucosal in-
flammation are prevalent,
28,29 although direct link between the 
mucosal inflammation and symptoms still remains to be 
controversial.
51,52
The patients with H. pylori infection having dyspeptic symp-
toms should be treated first as H. pylori infection with dyspepsia Kentaro Sugano
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instead of diagnosis then as functional dyspepsia having H. pylori 
infection because the spectrum of pathological as well as physio-
logical changes caused by H. pylori infection clearly deserve to be 
included in organic diseases. The residual dyspeptic symptoms 
after complete cure of H. pylori infection may be considered to be 
caused by coexisting “functional dyspepsia,” although complete 
resolution of submucosal inflammation after successful erad-
ication was shown to require a prolonged period.
53
In line with my proposal to separate the 2 entities, a similar 
naming (dyspepsia with H. pylori) was used in a recent proposal 
for the diagnostic algorithm of dyspepsia by a group of expert.
54
Conclusion
In order to unravel pathophysiological mechanisms of FD 
and to establish more precise diagnostic markers or criteria, we 
should exclude organic diseases with distinct etiology such as H. 
pylori infection from an umbrella category of functional dys-
pepsia. Functional disorder should be considered only when re-
sidual symptoms persist despite of successful treatment targeted 
to cure the organic diseases.
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